Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 22Colorectal Neoplasms 19Pancreatic Neoplasms 15Stomach Neoplasms 14Rectal Neoplasms 10Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Locally Advanced Rectal Cancer 6Carcinoma, Non-Small-Cell Lung 6Liver Neoplasms 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Sarcoma 4Melanoma 4Lung Neoplasms 4Gastrointestinal Stromal Tumors 4Endometrial Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Neoplasms 2Mesothelioma 2

Interventions

Gemcitabine 5130-nm albumin-bound paclitaxel 3Albumin-Bound Paclitaxel 2spartalizumab 1canakinumab 1Taxes 1SLC-0111 1IFL protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Ductal Adenocarcinoma × spartalizumab × Gastrointestinal × Clear all
NCT04581343 2025-05-04

PanCAN-SR1

Pancreatic Cancer Action Network

Phase 1 Completed
10 enrolled 26 charts
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡